8-K: Assertio Holdings Delays Tender Offer Commencement

Assertio Holdings and Garda Therapeutics mutually agree to postpone the tender offer commencement to May 8, 2026, impacting the acquisition timeline.

Summary

• Assertio Holdings, Inc. announced a mutual agreement with Garda Therapeutics, Inc. to postpone the commencement of the tender offer for Assertio's common stock.
• The tender offer, initially planned to commence on May 4, 2026, is now scheduled to begin on May 8, 2026.
• This postponement also affects the tender offer for all outstanding Convertible Senior Notes, which is also rescheduled to May 8, 2026.
• The acquisition agreement, dated May 1, 2026, involves Garda acquiring Assertio for $21.80 per share in cash, totaling $153.2 million.
• Assertio expects to file its Schedule 14D-9 in connection with the tender offer on May 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development; while the acquisition is proceeding, the delay introduces a minor uncertainty into the timeline.

Positives

• The acquisition terms remain unchanged, with Garda Therapeutics agreeing to acquire Assertio for $21.80 per share in cash, totaling $153.2 million.
• Both parties have mutually agreed to the postponement, indicating continued cooperation towards the transaction.

Negatives

• The commencement of the tender offer has been delayed, extending the uncertainty around the acquisition timeline.
• The postponement of the tender offer for Convertible Senior Notes could impact debt holders.

Risks

• Risks associated with the timing of the closing of the proposed transaction, including the possibility that a condition to closing would not be satisfied within the expected timeframe or at all.
• Uncertainties regarding the number of Assertio stockholders who will tender their shares in the offer.
• The possibility of competing offers being made.
• Potential prohibition, delay, or refusal of approval by a governmental entity.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the transaction.
• The outcome of any legal proceedings that may be instituted against the parties related to the transaction.
• Unanticipated difficulties or expenditures relating to the proposed transaction.
• The effect of the announcement or pendency of the proposed transaction on Assertio's business and operating results, including the response of business partners and competitors and potential difficulties in employee retention.

Future Outlook

The company expects to file its Schedule 14D-9 in connection with the tender offer on May 8, 2026. The tender offer for common stock and Convertible Senior Notes is now scheduled to commence on May 8, 2026.

Management Comments

• Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer.

Industry Context

StockSavvy.ai notes that delays in M&A transaction timelines are not uncommon, especially when regulatory filings or shareholder approvals are involved. This postponement by Assertio Holdings and Garda Therapeutics suggests a need for additional time to finalize necessary documentation or address potential concerns before the tender offer officially begins.

Legal Proceedings

• Potential legal proceedings related to the transaction are mentioned as a risk factor.

Stakeholder Impact

• Shareholders: The delay in the tender offer commencement may cause uncertainty regarding the timing of the cash payout. Investors are advised to read tender offer materials carefully.
• Noteholders: The postponement of the tender offer for Convertible Senior Notes affects the timing for holders of these notes.

Next Steps

• Assertio to file Schedule 14D-9 on May 8, 2026.
• Tender offer for common stock to commence on May 8, 2026.
• Tender offer for Convertible Senior Notes to commence on May 8, 2026.

Key Dates

Recommendation

The filing indicates a delay in the tender offer commencement, which is a procedural step in an agreed-upon acquisition. While the acquisition terms remain, the delay introduces a slight uncertainty. Investors should hold their position pending further developments and the official commencement of the tender offer.

Keywords

Assertio Holdings, Garda Therapeutics, Merger Agreement, Tender Offer, Acquisition, Convertible Senior Notes, SEC Filing, Form 8-K